Physician profile
Kurt King
NPI 1194795377
$2,651.07
in general payments reported to CMS, 2019-2025
20 companies · $96.89 in 2025
The $96.89 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $36.17 · 2021: $17.25 · 2022: $13.81 · 2023: $1,403 · 2024: $1,084 · 2025: $96.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,584.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $798.81 | 2022-2024 | |
| Pfizer INC. | $487.36 | 2020-2025 | |
| Novo Nordisk INC | $334.72 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $299.12 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $129.78 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $102.67 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.15 | 2023-2024 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $62.06 | 2023 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $53.69 | 2024 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.42 | 2023 | Jardiance, Tradjenta |
| Janssen Pharmaceuticals, INC | $44.68 | 2023-2024 | Xarelto |
| Amgen INC. | $44.64 | 2023-2024 | Otezla, Repatha |
| Astellas Pharma US INC | $33.45 | 2024 | Veozah |
| Regeneron Healthcare Solutions, INC. | $32.74 | 2024 | Dupixent |
| Cequr Corporation | $25.73 | 2023 | Cequr Simplicity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.20 | 2024 | Ibsrela |
| Lundbeck LLC | $18.47 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $17.30 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $15.90 | 2023 | Airduo Digihaler |
| E.R. Squibb & Sons, L.L.C. | $14.18 | 2023 | Camzyos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.